论文部分内容阅读
该项目在国际上率先发现一批新的白血病诊断和预后监测的分子标志和药物靶标,并成功研制了新型联合靶向疗法,使急性早幼粒细胞白血病(APL)成为第一个可治愈的髓系白血病。主要成果有:1.新型诊断与预后分子标志物和治疗靶标的发现:在国际上率先发现DNMT3A基因在急性单核细胞白血病中高频突变并提示不良预后;首次揭示M2t^AML中C-KI丁基因突变与AML1-ET0融合基因具协同作用;首先发现了一组新的染色体易位,并克
The project is the first in the world to identify a new set of molecular markers and drug targets for the diagnosis and prognosis of leukemia and has successfully developed a new combination of targeted therapies that make APL the first to be curable Myeloid leukemia. The main results are as follows: 1. The discovery of novel diagnostic and prognostic molecular markers and therapeutic targets: The first international discovery of DNMT3A gene mutation in acute monocytic leukemia and suggestive of poor prognosis; for the first time reveals the M2t ^ AML C-KI D Gene mutation and AML1-ET0 fusion gene has a synergistic effect; first found a new set of chromosome translocations, and grams